+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Presbyopia - Pipeline Review, H2 2019

  • ID: 4901299
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 49 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Acucela Inc
  • Allergan Plc
  • Cellix Bio Pvt Ltd
  • Eyenovia Inc
  • Kedalion Therapeutics Inc
  • Novartis AG
  • MORE
Presbyopia - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H2 2019, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 3 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acucela Inc
  • Allergan Plc
  • Cellix Bio Pvt Ltd
  • Eyenovia Inc
  • Kedalion Therapeutics Inc
  • Novartis AG
  • MORE
Introduction
Report Coverage
Presbyopia - Overview
Presbyopia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Presbyopia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Presbyopia - Companies Involved in Therapeutics Development
Acucela Inc
Allergan Plc
Cellix Bio Pvt Ltd
Eyenovia Inc
Kedalion Therapeutics Inc
Novartis AG
Ocuphire Pharma Inc
Orasis Pharmaceuticals Ltd
Plex Pharmaceuticals Inc
Presbyopia Therapies LLC
ViewPoint Therapeutics Inc
Presbyopia - Drug Profiles
Presbyopia - Dormant Projects
Presbyopia - Discontinued Products
Presbyopia - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Presbyopia, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Presbyopia - Pipeline by Acucela Inc, H2 2019
Presbyopia - Pipeline by Allergan Plc, H2 2019
Presbyopia - Pipeline by Cellix Bio Pvt Ltd, H2 2019
Presbyopia - Pipeline by Eyenovia Inc, H2 2019
Presbyopia - Pipeline by Kedalion Therapeutics Inc, H2 2019
Presbyopia - Pipeline by Novartis AG, H2 2019
Presbyopia - Pipeline by Ocuphire Pharma Inc, H2 2019
Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, H2 2019
Presbyopia - Pipeline by Plex Pharmaceuticals Inc, H2 2019
Presbyopia - Pipeline by Presbyopia Therapies LLC, H2 2019
Presbyopia - Pipeline by ViewPoint Therapeutics Inc, H2 2019
Presbyopia - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Presbyopia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acucela Inc
  • Allergan Plc
  • Cellix Bio Pvt Ltd
  • Eyenovia Inc
  • Kedalion Therapeutics Inc
  • Novartis AG
  • Ocuphire Pharma Inc
  • Orasis Pharmaceuticals Ltd
  • Plex Pharmaceuticals Inc
  • Presbyopia Therapies LLC
  • ViewPoint Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll